Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34839
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartin, Thomas John-
dc.contributor.authorSeeman, Ego-
dc.date2023-
dc.date.accessioned2024-01-11T02:02:26Z-
dc.date.available2024-01-11T02:02:26Z-
dc.date.issued2023-12-
dc.identifier.citationNeurospine 2023-12; 20(4)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34839-
dc.description.abstractBone is continuously in a state of building and renewal, though the process of remodeling that takes place at many sites asynchronously throughout the skeleton, with bone formation and resorption equal at these sites (bone multicellular units). Remodeling takes place on bone surfaces, both on trabeculae and in the cortex, and serves the purposes of replacing old bone or that damaged by microfractures throughout the skeleton. The bone loss and consequent osteoporotic fractures that result from excess resorption over formation have mainly been prevented or treated by antiresorptive drugs that inhibit osteoclast formation and/or activity. Virtually all of the evidence leading to acceptance of antiresorptive drugs as treatment has depended upon their prevention of vertebral fractures. In recent decades, new prospects came of anabolic treatments that partly restore bone volume and microstructure restore bone that has been lost. The first of these was parathyroid hormone (PTH), shown by daily injection to increase markers of bone formation and prevent fractures. This field of interest enlarged with the discovery of PTH-related protein (PTHrP), so closely related in structure and action to PTH. The structural relationship between PTH and PTHrP is important in assessing their physiological and pharmacological roles, with the N-terminal domains of the 2 having virtually equal actions on target cells. Abaloparatide, a peptide analogue based on the structures of PTHrP and PTH, has been approved in some countries as a therapy for osteoporosis. Treatment through the PTH receptor activation pathway, and probably with any anabolic therapy, needs to be followed by antiresorptive treatment in order to maintain bone that has been restored. No matter how effective anabolic therapies for the skeleton become, it seems highly likely that there will be a continuing need for antiresorptive drugs.en_US
dc.language.isoeng-
dc.subjectBone remodelingen_US
dc.subjectOsteoporosisen_US
dc.subjectParathyroid hormoneen_US
dc.subjectParathyroid hormonerelated proteinen_US
dc.subjectWnt signalingen_US
dc.titleBone Remodeling and Modeling: Cellular Targets for Antiresorptive and Anabolic Treatments, Including Approaches Through the Parathyroid Hormone (PTH)/PTH-Related Protein Pathway.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNeurospineen_US
dc.identifier.affiliationDepartment of Medicine and St. Vincent's Institute of Medical Research, University of Melbourne, Melbourne, Australia.en_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationMary MacKillop Institute of Health Research, Australian Catholic University, Melbourne, Australia.en_US
dc.identifier.doi10.14245/ns.2346966.483en_US
dc.type.contentTexten_US
dc.identifier.pubmedid38171279-
dc.description.volume20-
dc.description.issue4-
dc.description.startpage1097-
dc.description.endpage1109-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.